China approves Bio-Thera Solutions' biosimilar to Actemra

Published on January 19, 2023

The China National Medical Products Administration (NMPA) has approved BAT1806, a biosimilar of Actemra (tocilizumab), in China.

Continue reading on website
Other news

What's top-of-mind for biopharma executives in 2023?

January 19, 2023
Many life science professionals say they are âcautiously positiveâ about the outlook for their industry in 2023, although highlight it wonât be all plain sailing.

UK ATMP clinical research picture remains positive despite challenging global environment

January 19, 2023
In 2022, the UK continued to have a signficant footprint in ATMP clinical research, with total ongoing trials increasing from 168 in 2021 to 178 in 2022, according to a new report.